End Fatigue

Recruiting Patients with Chronic Fatigue Syndrome (Chronic Fatigue and Immune Dysfunction Syndrome) for Clinical Study

Note: The following is a reprinted announcement from Charles Drew University of LA, CA and is not a representation directly from Dr. Teitelbaum. Any questions regarding this should be sent to their representatives via study@goodhormonehealth.com. Personal references of "we" below refer to the university and are statements made by them, not Dr. T.

Purpose

The purpose of this study is to determine whether chronic fatigue syndrome (CFS) is due to inadequate blood flow to the brain and to test a medication which may help increase blood flow to the brain and improve the symptoms of CFS. We propose that in a subset of patients with CFS, there is inadequate blood flow to the brain, resulting in some of the symptoms of chronic fatigue syndrome. To determine if this is the case, you will have brain scans called SPECT scans, which measure blood flow to your brain. We will also do a test to measure your blood pressure in different positions, called a tilt-table test.

You will then receive drug or placebo (sugar-pill) in a blinded (such that neither you nor your doctors know if you are taking drug or placebo) manner as a possible treatment for CFS. We will test the idea that this drug will increase blood flow to the brain and improve symptoms related to CFS. We will also test if this drug improves your thinking process. It is expected that these tests will help allow doctors to understand what causes chronic fatigue syndrome.

Criteria for Subjects

Number of patients = 30

Location: The Charles Drew University in Willowbrook and Harbor-UCLA in Torrance. Both of these locations are in Los Angeles, CA.

Enrollment Period: on going

Patient Compensation: $200

For more information or subject referrals contact:

Ted Friedman, M.D., Ph.D. Clinical Director
Erik Zuckerbraun, M.D., Study Coordinator
Telephone (323) 563-9385
Email: study@goodhormonehealth.com